DSIP (Delta Sleep-Inducing Peptide)

Technical data

INN name

DSIP

CAS

62568-57-4

Molecular formula

C35H48N10O15

Molecular weight

848.89 g/mol

Identity and composition

El DSIP (Delta Sleep-Inducing Peptide) is a endogenous nonapeptide which has been investigated in preclinical models and in early human studies for its association with sleep regulation and delta EEG activity. It is offered in presentations of 5 mg, 10 mg and 15 mg. Product for research use.

Verifiable chemical identity data (reference block):

• Name: Delta Sleep-Inducing Peptide / Delta Sleep-Inducing Peptide
• Synonyms: Delta-sleep-inducing peptide, Delta EEG-inducing peptide, Emideltide, DSIP
• CAS: 62568-57-4
• Molecular formula: C35H48N10O15
• Molecular weight: ~848.8 g/mol (reported as ~849)
• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE); nonapeptide
• PubChem CID: 68816

These identity constants are confirmed in PubChem and in the reference literature and are presented only as characterization of the compound.

Mechanism of action

DSIP is an endogenous nonapeptide first isolated in the 1970s from the cerebral venous blood of rabbits in a sleep phase. In experimental models, its intraventricular infusion has been associated with a specific increase in EEG activity in the delta and spindle bands, rather than with classic pharmacological sedation; the foundational literature has reported a mean increase in delta activity of close to 35% versus controls (PMID 568769; PMID 6895513).

Beyond the effect on the EEG and sleep, the review by Graf and Kastin documents that DSIP-type material is distributed in the brain, peripheral organs, and plasma, and has been associated with the modulation of neurotransmitter levels, circadian/locomotor patterns, and hormonal levels (including HPA-related axes), with a dose- and time-response curve of the type non-linear (U-shaped) (PMID 6145137).

Note: receptor-level actions (for example, effects on GABA or NMDA currents) appear in secondary literature and were not confirmed in the primary sources reviewed; they are described here only as a contextual observation, not as an established mechanism.

Pharmacokinetics

No reliable data were confirmed for half-life, clearance, or volume of distribution in the reviewed sources. The available human study used a single intravenous dose of 25 nmol/kg, but did not report pharmacokinetic parameters (PMID 6895513).

For the above reasons, any quantitative characterization of DSIP kinetics must be considered not established with the evidence compiled here.

Scientific evidence

The evidence on DSIP is preliminary and limited, based mostly on experimental work from the 1970s and 1980s and on small early human studies; the existence of registered modern late-phase clinical trials could not be confirmed.

The human data come from small studies, such as an intravenous infusion in six healthy volunteers in which an increase in total sleep time and a shorter sleep-onset latency in the later phase were reported (PMID 6895513). The reference review notes broader putative functions in hormonal, circadian and neuropharmacological regulation (PMID 6145137).

These findings should be treated as preliminary and not as established clinical efficacy.

Research applications

Product for research use.

Ideal for:

• In vitro and preclinical-model studies on sleep regulation and EEG activity (delta/spindles).
• Exploratory research on neuroendocrine, circadian and neurotransmitter pathways described in the reference literature.
• Methodological laboratory work (peptide characterization, assay development).

Not applicable for:

• Any diagnostic, therapeutic, clinical, or veterinary use.
• Self-administration or clinical formulation.
• Efficacy conclusions: the available evidence is preliminary and does not support clinical indications.

Research protocols

The doses reported in the literature correspond to research contexts and do not constitute a usage guideline. In the available human study, one single intravenous dose of 25 nmol/kg in six volunteers (PMID 6895513).

In the reference experimental works, the effects on the EEG were observed after intraventricular infusion in animal models, not by administration routes standardized for humans (PMID 568769; PMID 6145137).

No additional validated dosing schemes are available in the reviewed sources; any protocol must be defined by the researcher according to their experimental design.

Reconstitution

As a standard general laboratory guideline for lyophilized peptides:

• Reconstitute with bacteriostatic water (sterile water with ~0.9% benzyl alcohol) for multi-use research, or with sterile water for injection when the design requires it.
• Add the diluent letting it run down the wall of the vial, without directing the stream directly onto the powder, to minimize mechanical degradation.
• Swirl gently until completely dissolved; do not shake vigorously.
• Calculate the concentration according to the milligrams of the vial (5, 10, or 15 mg) and the diluent volume used, to determine the volume per aliquot in the protocol.

Stability and storage

Standard laboratory handling for peptides:

• Lyophilized (powder): it is the most stable form; it is usually stored refrigerated and, for prolonged storage, frozen, protected from light and humidity.
• Reconstituted (in solution): maintain refrigerated and use it within a short time window, since peptides in solution are less stable.
• Avoid repeated freeze-thaw cycles; consider aliquots to reduce handling of the main vial.
• Label with reconstitution date and concentration.

These are general storage practices; they do not replace the specific conditions validated by each laboratory.

Safety profile

The documented safety profile is very limited. In the small human intravenous study (n=6), DSIP was reported as well tolerated, with no adverse psychological, physiological, or biochemical effects observed (PMID 6895513).

These are early, small-sample data that do not constitute a complete safety profile; the review by Graf and Kastin provides no detailed data on toxicity or contraindications (PMID 6145137). No validated information is available on interactions, special populations, or chronic exposure.

As a research material, it must be handled with standard laboratory precautions and with no destination for clinical use.

Comparative context

Unlike conventional sedative-hypnotics, the early human study explicitly noted that DSIP did not produce sedation "in the classic pharmacological manner", which suggests that it is associated with the facilitation of the endogenous architecture of sleep (enhancement of delta activity) rather than a depression of the central nervous system (PMID 6895513).

In terms of class, DSIP is a endogenous signaling peptide, not a CNS depressant molecule; its described response is non-linear (U-shaped) with respect to dose and time (PMID 6145137), a pattern different from that of agents with a more direct dose-effect relationship.

No direct head-to-head comparisons with other compounds were confirmed.

History and development

DSIP was first isolated in the 1970s from the cerebral venous blood of rabbits in the sleep phase, and its name derives from this due to its association with the induction of delta EEG activity. Its sequence as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was characterized through amino acid analysis, sequencing, and synthesis, confirming its activity on delta and spindle EEG (PMID 568769).

The consolidation of knowledge about the compound was captured in the review by Graf and Kastin, which described its endogenous distribution and its putative multiple functions (EEG, neurotransmitters, circadian rhythms, and hormone levels) (PMID 6145137). Subsequent work in humans was limited to small early-phase studies (PMID 6895513), without advancing toward confirmed registered late-phase trials.

FAQ

Customer reviews

Average rating: 4.8 out of 5, based on 10 customer ratings.

Certificate of analysis per batch

DSIP (Delta Sleep-Inducing Peptide) batches with a certificate of analysis published in the COA catalog:

• Lot EXO010626134A — 5 mg, issued 2026-05-29
• Lot EXO010626134C — 10 mg, issued 2026-05-30

Scientific references (6)

Peer-reviewed literature on DSIP (Delta Sleep Inducing Peptide), with its PubMed identifier when available:

• Delta-sleep-inducing peptide (DSIP): a review (Graf MV, et al. · Neuroscience & Biobehavioral Reviews · 1984) — Review of DSIP: isolation, characterization, and available evidence on its reported effects on sleep. PMID 6145137.
• Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. (Schneider-Helmert D, et al. · Lancet · 1981) PMID 6112579.
• Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. (Backmund M, et al. · J Clin Psychopharmacol · 1998) PMID 9617990.
• Characterization of a delta-electroencephalogram (-sleep)-inducing peptide (Schoenenberger, et al. · Proceedings of the National Academy of Sciences (PNAS) · 1977) PMID 265572.
• A clinical trial with DSIP (Kaeser · European Neurology · 1984) PMID 6391926.
• Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study (Bes, et al. · Neuropsychobiology · 1992) PMID 1299794.

Guides and articles on DSIP (Delta Sleep-Inducing Peptide)

Lecturas del blog de EXOMA que la editorial asoció a este compuesto:

• DSIP: The Delta Sleep-Inducing Peptide in Research

Other related research peptides

• Basic GHK
• GHK-Cu
• GLOW
• HGH (Somatropin)
• IGF-1 LR3
• KLOW
• KPV
• Matrixyl
• MGF
• PEG MGF